Hepatitis C: Current options for nonresponders to peginterferon and ribavirin

Emmanuel Thomas, Michael W. Fried

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hepatitis C virus infection remains a significant health problem worldwide. The development of interferon-based therapies has led to increased success in eradicating this viral infection; however, no recent additions to the current treatment care regimen (peginterferon and ribavirin) have been made. Nonresponders to peginterferon/ribavirin make up a diverse patient population that can be difficult to manage. Through a better understanding of treatment response and viral kinetics, clinicians are employing altered dosing schedules to minimize the burden of viral illness. Consequently, clinicians can now manage nonresponders by providing supportive care and reserving retreatment for those most likely to respond to additional antiviral therapy, particularly when correctable factors from a previous treatment course with the potential for positive intervention have been identified. The decision for further medical management is based on clinical and laboratory parameters that have been shown to predict which patients will benefit most from another attempt at therapy.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalCurrent Gastroenterology Reports
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Ribavirin
Hepatitis C
Virus Diseases
Therapeutics
Cost of Illness
Retreatment
Hepacivirus
Interferons
Antiviral Agents
Appointments and Schedules
Population

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Hepatitis C : Current options for nonresponders to peginterferon and ribavirin. / Thomas, Emmanuel; Fried, Michael W.

In: Current Gastroenterology Reports, Vol. 10, No. 1, 01.12.2008, p. 53-59.

Research output: Contribution to journalArticle

@article{ec22c89e43914cf18ab5534c3d98e32d,
title = "Hepatitis C: Current options for nonresponders to peginterferon and ribavirin",
abstract = "Hepatitis C virus infection remains a significant health problem worldwide. The development of interferon-based therapies has led to increased success in eradicating this viral infection; however, no recent additions to the current treatment care regimen (peginterferon and ribavirin) have been made. Nonresponders to peginterferon/ribavirin make up a diverse patient population that can be difficult to manage. Through a better understanding of treatment response and viral kinetics, clinicians are employing altered dosing schedules to minimize the burden of viral illness. Consequently, clinicians can now manage nonresponders by providing supportive care and reserving retreatment for those most likely to respond to additional antiviral therapy, particularly when correctable factors from a previous treatment course with the potential for positive intervention have been identified. The decision for further medical management is based on clinical and laboratory parameters that have been shown to predict which patients will benefit most from another attempt at therapy.",
author = "Emmanuel Thomas and Fried, {Michael W.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s11894-008-0009-8",
language = "English",
volume = "10",
pages = "53--59",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Hepatitis C

T2 - Current options for nonresponders to peginterferon and ribavirin

AU - Thomas, Emmanuel

AU - Fried, Michael W.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Hepatitis C virus infection remains a significant health problem worldwide. The development of interferon-based therapies has led to increased success in eradicating this viral infection; however, no recent additions to the current treatment care regimen (peginterferon and ribavirin) have been made. Nonresponders to peginterferon/ribavirin make up a diverse patient population that can be difficult to manage. Through a better understanding of treatment response and viral kinetics, clinicians are employing altered dosing schedules to minimize the burden of viral illness. Consequently, clinicians can now manage nonresponders by providing supportive care and reserving retreatment for those most likely to respond to additional antiviral therapy, particularly when correctable factors from a previous treatment course with the potential for positive intervention have been identified. The decision for further medical management is based on clinical and laboratory parameters that have been shown to predict which patients will benefit most from another attempt at therapy.

AB - Hepatitis C virus infection remains a significant health problem worldwide. The development of interferon-based therapies has led to increased success in eradicating this viral infection; however, no recent additions to the current treatment care regimen (peginterferon and ribavirin) have been made. Nonresponders to peginterferon/ribavirin make up a diverse patient population that can be difficult to manage. Through a better understanding of treatment response and viral kinetics, clinicians are employing altered dosing schedules to minimize the burden of viral illness. Consequently, clinicians can now manage nonresponders by providing supportive care and reserving retreatment for those most likely to respond to additional antiviral therapy, particularly when correctable factors from a previous treatment course with the potential for positive intervention have been identified. The decision for further medical management is based on clinical and laboratory parameters that have been shown to predict which patients will benefit most from another attempt at therapy.

UR - http://www.scopus.com/inward/record.url?scp=51549111262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51549111262&partnerID=8YFLogxK

U2 - 10.1007/s11894-008-0009-8

DO - 10.1007/s11894-008-0009-8

M3 - Article

C2 - 18417043

AN - SCOPUS:51549111262

VL - 10

SP - 53

EP - 59

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 1

ER -